MDLN earnings analysis
What we found in MDLN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Medline's Q1 2026 results show a strong increase in revenue of 10.7% year-over-year, reaching $7.4 billion, surpassing analyst estimates. However, the company faced a significant decline in net income and gross margins, impacted by rising costs associated with tariffs, which contributed to a dip in profitability as reflected in the lower EPS at $0.33 compared to $0.29 estimated and net income margin of 3.3%. Despite these challenges, management raised guidance for organic sales growth for the year to a range of 8.5%-9.5%.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surged 10.7% YOY
- Net sales reached $7.4 billion, up from $6.6 billion a year ago.
- EPS Exceeds Estimates
- Reported EPS was $0.33, beating the estimated $0.29, marking a surprise of 13.8%.
- Effective Management of Debt Costs
- Interest expense decreased by 35.2%, from $210 million to $136 million.
- Organic Sales Guidance Raised
- Management set a new organic growth forecast of 8.5% to 9.5% for the full year.
- Medline Brand Revenue Growth
- Medline Brand sales grew 6.2% to $3.465 billion, driven by volume growth.
- Strong Cash Position
- Cash equivalents stood at $2.236 billion, providing a solid liquidity buffer.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Declining Gross Margins
- Gross profit margin decreased from 27.5% to 25.0%, primarily due to tariffs.
- Net Income Drop
- Net income fell 25.8% to $239 million from $322 million a year ago.
- Working Capital Strain
- Net cash from operations dropped to $412 million, down from $682 million, impacted by increased trade receivables.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.33
- Gross margin
- 25.0%
- Segment
- Medline Brand: $3,465 million, Supply Chain Solutions: $3,887 million
What they said about what is next.
Outlook includes revised organic sales growth guidance of 8.5% to 9.5% for the year.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 25, 2026
- Medline reports strong 2025 results with net sales up 11.5% to $28.432 billion and Adjusted EBITDA of $3.5 billion (12.2% margin). Growth was driven by Prime Vendor expansion (over 1,600 relationships, $18.0 billion in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MDLN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever